medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/ms2025-534medsovet-9730Research ArticleНЕЙРОДЕГЕНЕРАТИВНЫЕ ЗАБОЛЕВАНИЯNEURODEGENERATIVE DISEASESТранскраниальная электрическая стимуляция при болезни Паркинсона с ранним дебютомTranscranial direct current stimulation in early-onset Parkinson’s diseasehttps://orcid.org/0000-0002-6928-2355БордовскийС. П.BordovskyS. P.

Бордовский Сергей Петрович, аспирант кафедры нервных болезней Института клинической медицины имени Н.В. Склифосовского

119991, Москва, ул. Трубецкая, д. 8, стр. 2

Sergey P. Bordovsky, Postgraduate Student of the Department of Nervous Diseases, Sklifosovsky Institute of Clinical Medicine

8, Bldg. 2, Trubetskaya St., Moscow, 119991

sbordoche@gmail.comhttps://orcid.org/0009-0002-2305-7272ДударовM. Р.DudarovM. R.

Дударов Микаил Рустамович, студент Института клинической медицины имени Н.В. Склифосовского

119991, Москва, ул. Трубецкая, д. 8, стр. 2

Mikail R. Dudarov, Student, Sklifosovsky Institute of Clinical Medicine

8, Bldg. 2, Trubetskaya St., Moscow, 119991

mikail02@mail.ruhttps://orcid.org/0009-0005-7379-1485ВарфоломееваА. В.VarfolomeevaA. V.

Варфоломеева Арина Вячеславовна, студент Института клинической медицины имени Н.В. Склифосовского

119991, Москва, ул. Трубецкая, д. 8, стр. 2

Arina V. Varfolomeeva, Student, Sklifosovsky Institute of Clinical Medicine

8, Bldg. 2, Trubetskaya St., Moscow, 119991

artider@yahoo.comhttps://orcid.org/0009-0007-0682-4886КожинаА. А.KozhinaA. A.

Кожина Анастасия Антоновна, студент Института клинической медицины имени Н.В. Склифосовского

119991, Москва, ул. Трубецкая, д. 8, стр. 2

Anastasiia A. Kozhina, Student, Sklifosovsky Institute of Clinical Medicine

8, Bldg. 2, Trubetskaya St., Moscow, 119991

nastya.kozhina.01@mail.ruhttps://orcid.org/0009-0004-8656-1518ПоловинкоА. Л.PolovinkoA. L.

Половинко Арсений Львович, студент Института клинической медицины имени Н.В. Склифосовского

119991, Москва, ул. Трубецкая, д. 8, стр. 2

Arseny L. Polovinko, Student, Sklifosovsky Institute of Clinical Medicine

8, Bldg. 2, Trubetskaya St., Moscow, 119991

arsmarsgo@gmail.comhttps://orcid.org/0009-0000-5492-9411МакаровА. А.MakarovA. A.

Макаров Андрей Алексеевич, студент Института клинической медицины имени Н.В. Склифосовского

119991, Москва, ул. Трубецкая, д. 8, стр. 2

Andrey A. Makarov, Student, Sklifosovsky Institute of Clinical Medicine

8, Bldg. 2, Trubetskaya St., Moscow, 119991

andrewmakarovas@yandex.ruhttps://orcid.org/0000-0001-9734-7606АндреевС. С.AndreevS. S.

Андреев Сергей Степанович, стажер-исследователь Центра нейроэкономики и когнитивных исследований, Институт когнитивных нейронаук

101000, Москва, ул. Мясницкая, д. 20

Sergey S. Andreev, Research Intern, Centre for Cognition and Decision Making, Institute for Cognitive Neuroscience

20, Myasnitskaya St., Moscow, 101000

ssandreev@hse.ruhttps://orcid.org/0009-0005-4971-9651МуртазинаР. Т.MurtazinaR. T.

Муртазина Рената Тимуровна, стажер-исследователь кафедры нервных болезней Института клинической медицины имени Н.В. Склифосовского, ординатор Клиники нервных болезней имени А.Я. Кожевникова

119991, Москва, ул. Трубецкая, д. 8, стр. 2

Renata T. Murtazina, Research Intern of the Department of Nervous Diseases, Sklifosovsky Institute of Clinical Medicine, Resident of the Kozhevnikov Clinic of Nervous Diseases

8, Bldg. 2, Trubetskaya St., Moscow, 119991

renatamurtazina@mail.ruhttps://orcid.org/0000-0002-9228-5108ШевцоваК. В.ShevtsovaK. V.

Шевцова Ксения Викторовна, к.м.н., ассистент кафедры нервных болезней Института клинической медицины имени Н.В. Склифосовского

119991, Москва, ул. Трубецкая, д. 8, стр. 2

Kseniya V. Shevtsova, Cand. Sci. (Med.), Assistant of the Department of Nervous Diseases, Sklifosovsky Institute of Clinical Medicine

8, Bldg. 2, Trubetskaya St., Moscow, 119991

dr.kseniya.shevtsova@gmail.comПервый Московский государственный медицинский университет имени И.М. Сеченова (Сеченовский Университет)РоссияSechenov First Moscow State Medical University (Sechenov University)Russian FederationНациональный исследовательский университет «Высшая школа экономики»РоссияHSE UniversityRussian Federation202511012026022144151Copyright © Бордовский С.П., Дударов M.Р., Варфоломеева А.В., Кожина А.А., Половинко А.Л., Макаров А.А., Андреев С.С., Муртазина Р.Т., Шевцова К.В., 20262026Бордовский С.П., Дударов M.Р., Варфоломеева А.В., Кожина А.А., Половинко А.Л., Макаров А.А., Андреев С.С., Муртазина Р.Т., Шевцова К.В.Bordovsky S.P., Dudarov M.R., Varfolomeeva A.V., Kozhina A.A., Polovinko A.L., Makarov A.A., Andreev S.S., Murtazina R.T., Shevtsova K.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/9730Введение

Введение. Транскраниальная стимуляция постоянным током (ТСПТ) применяется как новый вспомогательный метод лечения моторных симптомов болезни Паркинсона (БП), однако ее эффективность и безопасность при раннем дебюте БП остаются недостаточно изученными.

Цель

Цель. Оценить влияние курса анодной ТСПТ на двигательные, когнитивные и аффективные функции пациентов с БП раннего дебюта.

Материалы и методы

Материалы и методы. В проспективное исследование были включены 5 пациентов с БП раннего дебюта (возраст 37–49 лет, средняя длительность заболевания 3,3 ± 4,7 года). Все пациенты получали стандартную противопаркинсоническую терапию и курс из 10 сеансов анодной ТСПТ (2 мА, 20 мин, ежедневно в течение 2 нед.). Оценивались моторные функции (UPDRS-III), когнитивный статус (MoCA, FAB, TMT-А/В) и аффективные показатели (шкала депрессии Бека, шкала личностной и ситуативной тревожности Спилбергера, шкала апатии) до и после курса.

Результаты

Результаты. После завершения курса средний балл по шкале UPDRS-III снизился на 19–20% (p < 0,05), что свидетельствует об улучшении моторных симптомов. Когнитивные (MoCA, FAB, TMT) и эмоциональные (BDI, STAI, шкала апатии) показатели продемонстрировали положительную, но статистически недостоверную динамику. Побочные эффекты не зарегистрированы, процедуры хорошо переносились всеми пациентами.

Заключение

Заключение. Полученные данные указывают на потенциальную эффективность и высокий профиль безопасности анодной ТСПТ при БП раннего дебюта. ТСПТ является неинвазивным и простым в применении методом нейромодуляции, хорошо переносимым пациентами, что делает ее перспективным дополнением к стандартной терапии. Для подтверждения результатов необходимы дальнейшие крупномасштабные рандомизированные исследования с длительным клиническим наблюдением.

Introduction

Introduction. Transcranial direct current stimulation (tDCS) is a novel adjunctive method for treating Parkinson’s disease (PD) symptoms. However, its efficacy and safety in patients with early-onset PD remain insufficiently studied.

Aim

Aim. To evaluate the effect of a course of anodal tDCS on motor, cognitive, and affective functions in patients with earlyonset PD.

Materials and methods

Materials and methods. In this prospective study, five patients (aged 37–49 years) with clinically confirmed PD (mean disease duration 3.3 ± 4.7 years) were included. All patients received standard antiparkinsonian therapy and a course of 10 anodal tDCS sessions (2 mA, 20 min each, daily for 2 weeks). Motor function (UPDRS-III), cognitive status (MoCA, FAB, TMT-A/B), and affective measures (Beck Depression Inventory, State-Trait Anxiety Inventory, Apathy Scale) were assessed before and after the course.

Results

Results. After completing the tDCS course, the mean UPDRS-III score significantly decreased by 19–20 % (p < 0.05), indicating improved motor function. Cognitive (MoCA, FAB, TMT) and affective (BDI, STAI, Apathy Scale) scores improved slightly but not significantly. No adverse events or dropouts occurred, the procedures were well tolerated by all participants.

Conclusion

Conclusion. These results suggest potential efficacy and a high safety profile of anodal tDCS as an adjunctive therapy in earlyonset PD. As a non-invasive, easily administered technique, tDCS is a promising tool for neuromodulation and rehabilitation in PD. However, further larger randomized trials with long-term follow-up are warranted to confirm these findings.

 

 

болезнь Паркинсона с ранним дебютомтранскраниальная электрическая стимуляциянейромодуляцияТСПТдвигательные нарушениякогнитивные нарушенияаффективные нарушенияearly-onset Parkinson’s diseasetranscranial direct current stimulationneuromodulationtDCSmotor disorderscognitive impairmentaffective disordersReferencesRaza C, Anjum R, Shakeel NUA. Parkinson’s disease: Mechanisms, translational models and management strategies. Life Sci. 2019;226:77–90. https://doi.org/10.1016/j.lfs.2019.03.057.Raza C, Anjum R, Shakeel NUA. Parkinson’s disease: Mechanisms, translational models and management strategies. Life Sci. 2019;226:77–90. https://doi.org/10.1016/j.lfs.2019.03.057.Thomas B, Beal MF. Parkinson’s disease. Hum Mol Genet. 2007;16(R2): R183–R194. https://doi.org/10.1093/HMG/DDM159.Thomas B, Beal MF. Parkinson’s disease. Hum Mol Genet. 2007;16(R2): R183–R194. https://doi.org/10.1093/HMG/DDM159.Camerucci E, Mullan AF, Turcano P, Bower J, Piat C, Ahlskog JE, Savica R. 40-Year Incidence of Early-Onset Parkinson’s Disease in Southeast Minnesota. J Parkinsons Dis. 2023;13(6):893–898. https://doi.org/10.3233/JPD-230049.Camerucci E, Mullan AF, Turcano P, Bower J, Piat C, Ahlskog JE, Savica R. 40-Year Incidence of Early-Onset Parkinson’s Disease in Southeast Minnesota. J Parkinsons Dis. 2023;13(6):893–898. https://doi.org/10.3233/JPD-230049.Mehanna R, Smilowska K, Fleisher J, Post B, Hatano T, Pimentel Piemonte ME et al. Age Cutoff for Early-Onset Parkinson’s Disease: Recommendations from the International Parkinson and Movement Disorder Society Task Force on Early Onset Parkinson’s Disease. Mov Disord Clin Pract. 2022;9(7):869–878. https://doi.org/10.1002/MDC3.13523.Mehanna R, Smilowska K, Fleisher J, Post B, Hatano T, Pimentel Piemonte ME et al. Age Cutoff for Early-Onset Parkinson’s Disease: Recommendations from the International Parkinson and Movement Disorder Society Task Force on Early Onset Parkinson’s Disease. Mov Disord Clin Pract. 2022;9(7):869–878. https://doi.org/10.1002/MDC3.13523.Thomsen TR, Rodnitzky RL. Juvenile parkinsonism: epidemiology, diagnosis and treatment. CNS Drugs. 2010;24(6):467–477. https://doi.org/10.2165/11533130-000000000-00000.Thomsen TR, Rodnitzky RL. Juvenile parkinsonism: epidemiology, diagnosis and treatment. CNS Drugs. 2010;24(6):467–477. https://doi.org/10.2165/11533130-000000000-00000.Salles PA, Pizarro-Correa X, Chaná-Cuevas P. Genetics of Parkinson´s disease: Recessive forms. Neurol Perspect. 2024;4(2):100147. https://doi.org/10.1016/j.neurop.2024.100147.Salles PA, Pizarro-Correa X, Chaná-Cuevas P. Genetics of Parkinson´s disease: Recessive forms. Neurol Perspect. 2024;4(2):100147. https://doi.org/10.1016/j.neurop.2024.100147.Schrag A, Ben-Shlomo Y, Brown R, Marsden CD, Quinn N. Young-onset Parkinson’s disease revisited – clinical features, natural history, and mortality. Mov Disord. 1998;13(6):885–894. https://doi.org/10.1002/MDS.870130605.Schrag A, Ben-Shlomo Y, Brown R, Marsden CD, Quinn N. Young-onset Parkinson’s disease revisited – clinical features, natural history, and mortality. Mov Disord. 1998;13(6):885–894. https://doi.org/10.1002/MDS.870130605.Riboldi GM, Frattini E, Monfrini E, Frucht SJ, Di Fonzo A. A Practical Approach to Early-Onset Parkinsonism. J Parkinsons Dis. 2022;12(1):1–26. https://doi.org/10.3233/JPD-212815.Riboldi GM, Frattini E, Monfrini E, Frucht SJ, Di Fonzo A. A Practical Approach to Early-Onset Parkinsonism. J Parkinsons Dis. 2022;12(1):1–26. https://doi.org/10.3233/JPD-212815.Koros C, Simitsi AM, Papagiannakis N, Bougea A, Antonelou R, Pachi I et al. Precision Dopaminergic Treatment in a Cohort of Parkinson’s Disease Patients Carrying Autosomal Recessive Gene Variants: Clinical Cohort Data and a Mini Review. Neurol Int. 2024;16(4):833–844. https://doi.org/10.3390/NEUROLINT16040062.Koros C, Simitsi AM, Papagiannakis N, Bougea A, Antonelou R, Pachi I et al. Precision Dopaminergic Treatment in a Cohort of Parkinson’s Disease Patients Carrying Autosomal Recessive Gene Variants: Clinical Cohort Data and a Mini Review. Neurol Int. 2024;16(4):833–844. https://doi.org/10.3390/NEUROLINT16040062.Kostić VS. Treatment of young-onset Parkinson’s disease: role of dopamine receptor agonists. Parkinsonism Relat Disord. 2009;15(Suppl. 4):S71–S75. https://doi.org/10.1016/S1353-8020(09)70839-9.Kostić VS. Treatment of young-onset Parkinson’s disease: role of dopamine receptor agonists. Parkinsonism Relat Disord. 2009;15(Suppl. 4):S71–S75. https://doi.org/10.1016/S1353-8020(09)70839-9.Su D, Cui Y, He C, Yin P, Bai R, Zhu J et al. Projections for prevalence of Parkinson’s disease and its driving factors in 195 countries and territories to 2050: modelling study of Global Burden of Disease Study 2021. BMJ. 2025;388:e080952. https://doi.org/10.1136/BMJ-2024-080952.Su D, Cui Y, He C, Yin P, Bai R, Zhu J et al. Projections for prevalence of Parkinson’s disease and its driving factors in 195 countries and territories to 2050: modelling study of Global Burden of Disease Study 2021. BMJ. 2025;388:e080952. https://doi.org/10.1136/BMJ-2024-080952.Pringsheim T, Jette N, Frolkis A, Steeves TD. The prevalence of Parkinson’s disease: a systematic review and meta-analysis. Mov Disord. 2014;29(13):1583–1590. https://doi.org/10.1002/MDS.25945.Pringsheim T, Jette N, Frolkis A, Steeves TD. The prevalence of Parkinson’s disease: a systematic review and meta-analysis. Mov Disord. 2014;29(13):1583–1590. https://doi.org/10.1002/MDS.25945.Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology. 2007;68(5):384–386. https://doi.org/10.1212/01.WNL.0000247740.47667.03.Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology. 2007;68(5):384–386. https://doi.org/10.1212/01.WNL.0000247740.47667.03.Simon DK, Tanner CM, Brundin P. Parkinson Disease Epidemiology, Pathology, Genetics, and Pathophysiology. Clin Geriatr Med. 2020;36(1):1–12. https://doi.org/10.1016/J.CGER.2019.08.002.Simon DK, Tanner CM, Brundin P. Parkinson Disease Epidemiology, Pathology, Genetics, and Pathophysiology. Clin Geriatr Med. 2020;36(1):1–12. https://doi.org/10.1016/J.CGER.2019.08.002.Gibb WR, Lees AJ. A comparison of clinical and pathological features of young- and old-onset Parkinson’s disease. Neurology. 1988;38(9):1402–1406. https://doi.org/10.1212/WNL.38.9.1402.Gibb WR, Lees AJ. A comparison of clinical and pathological features of young- and old-onset Parkinson’s disease. Neurology. 1988;38(9):1402–1406. https://doi.org/10.1212/WNL.38.9.1402.Ylikotila P, Tiirikka T, Moilanen JS, Kääriäinen H, Marttila R, Majamaa K. Epidemiology of early-onset Parkinson’s disease in Finland. Parkinsonism Relat Disord. 2015;21(8):938–942. https://doi.org/10.1016/j.parkreldis.2015.06.003.Ylikotila P, Tiirikka T, Moilanen JS, Kääriäinen H, Marttila R, Majamaa K. Epidemiology of early-onset Parkinson’s disease in Finland. Parkinsonism Relat Disord. 2015;21(8):938–942. https://doi.org/10.1016/j.parkreldis.2015.06.003.Alves G, Wentzel-Larsen T, Aarsland D, Larsen JP. Progression of motor impairment and disability in Parkinson disease: a population-based study. Neurology. 2005;65(9):1436–1441. https://doi.org/10.1212/01.WNL.0000183359.50822.F2.Alves G, Wentzel-Larsen T, Aarsland D, Larsen JP. Progression of motor impairment and disability in Parkinson disease: a population-based study. Neurology. 2005;65(9):1436–1441. https://doi.org/10.1212/01.WNL.0000183359.50822.F2.de Bie RMA, Clarke CE, Espay AJ, Fox SH, Lang AE. Initiation of pharmacological therapy in Parkinson’s disease: when, why, and how. Lancet Neurol. 2020;19(5):452–461. https://doi.org/10.1016/S1474-4422(20)30036-3.de Bie RMA, Clarke CE, Espay AJ, Fox SH, Lang AE. Initiation of pharmacological therapy in Parkinson’s disease: when, why, and how. Lancet Neurol. 2020;19(5):452–461. https://doi.org/10.1016/S1474-4422(20)30036-3.Zhang X, Huai Y, Wei Z, Yang W, Xie Q, Yi L. Non-invasive brain stimulation therapy on neurological symptoms in patients with multiple sclerosis: A network meta analysis. Front Neurol. 2022;13:1007702. https://doi.org/10.3389/FNEUR.2022.1007702.Zhang X, Huai Y, Wei Z, Yang W, Xie Q, Yi L. Non-invasive brain stimulation therapy on neurological symptoms in patients with multiple sclerosis: A network meta analysis. Front Neurol. 2022;13:1007702. https://doi.org/10.3389/FNEUR.2022.1007702.Бордовский СП, Муртазина РТ, Андреев СС, Меинова ТО, Горлова ЮИ, Таранова АД и др. Транскраниальная электрическая стимуляция постоянным током при болезни Паркинсона. Медицинский совет. 2025;19(12):82–91. https://doi.org/10.21518/MS2025-228.Bordovsky SP, Murtazina RT, Andreev SS, Meinova TO, Gorlova IuI, Taranova AD et al. Transcranial direct current stimulation in Parkinson’s disease. Meditsinskiy Sovet. 2025;19(12):82–91. (In Russ.) https://doi.org/10.21518/MS2025-228.Lewis A, Rattray B, Flood A. Optimising transcranial direct current stimulation application for the enhancement of exercise performance: a review. Front Physiol. 2025;16:1672603. https://doi.org/10.3389/FPHYS.2025.1672603.Lewis A, Rattray B, Flood A. Optimising transcranial direct current stimulation application for the enhancement of exercise performance: a review. Front Physiol. 2025;16:1672603. https://doi.org/10.3389/FPHYS.2025.1672603.Bordovsky S, Andreev S, Murtazina R, Kotenko V, Takhirov R, Gorlova J et al. Targeted tDCS with small electrodes as a promising adjunctive therapy for Parkinson’s Disease. Brain Stimul. 2025;18(1):427–428. https://doi.org/10.1016/J.BRS.2024.12.630.Bordovsky S, Andreev S, Murtazina R, Kotenko V, Takhirov R, Gorlova J et al. Targeted tDCS with small electrodes as a promising adjunctive therapy for Parkinson’s Disease. Brain Stimul. 2025;18(1):427–428. https://doi.org/10.1016/J.BRS.2024.12.630.Duan Z, Zhang C. Transcranial direct current stimulation for Parkinson’s disease: systematic review and meta-analysis of motor and cognitive effects. NPJ Parkinsons Dis. 2024;10(1):214. https://doi.org/10.1038/s41531-024-00821-z.Duan Z, Zhang C. Transcranial direct current stimulation for Parkinson’s disease: systematic review and meta-analysis of motor and cognitive effects. NPJ Parkinsons Dis. 2024;10(1):214. https://doi.org/10.1038/s41531-024-00821-z.Starkstein SE, Mayberg HS, Preziosi TJ, Andrezejewski P, Leiguarda R, Robinson RG. Reliability, validity, and clinical correlates of apathy in Parkinson’s disease. J Neuropsychiatry Clin Neurosci. 1992;4(2):134–139. https://doi.org/10.1176/JNP.4.2.134.Starkstein SE, Mayberg HS, Preziosi TJ, Andrezejewski P, Leiguarda R, Robinson RG. Reliability, validity, and clinical correlates of apathy in Parkinson’s disease. J Neuropsychiatry Clin Neurosci. 1992;4(2):134–139. https://doi.org/10.1176/JNP.4.2.134.Chen Y, Jiang H, Wei Y, Ye S, Jiang J, Mak MKY et al. Effects of non-invasive brain stimulation over the supplementary motor area on motor function in Parkinson’s disease: A systematic review and meta-analysis. Brain Stimul. 2025;18(1):1–14. https://doi.org/10.1016/J.BRS.2024.12.005.Chen Y, Jiang H, Wei Y, Ye S, Jiang J, Mak MKY et al. Effects of non-invasive brain stimulation over the supplementary motor area on motor function in Parkinson’s disease: A systematic review and meta-analysis. Brain Stimul. 2025;18(1):1–14. https://doi.org/10.1016/J.BRS.2024.12.005.Lee H, Choi BJ, Kang N. Non-invasive brain stimulation enhances motor and cognitive performances during dual tasks in patients with Parkinson’s disease: a systematic review and meta-analysis. J Neuroeng Rehabil. 2024;21(1):205. https://doi.org/10.1186/S12984-024-01505-8.Lee H, Choi BJ, Kang N. Non-invasive brain stimulation enhances motor and cognitive performances during dual tasks in patients with Parkinson’s disease: a systematic review and meta-analysis. J Neuroeng Rehabil. 2024;21(1):205. https://doi.org/10.1186/S12984-024-01505-8.Liu X, Liu H, Liu Z, Rao J, Wang J, Wang P et al. Transcranial Direct Current Stimulation for Parkinson’s Disease: A Systematic Review and Meta-Analysis. Front Aging Neurosci. 2021;13:746797. https://doi.org/10.3389/FNAGI.2021.746797.Liu X, Liu H, Liu Z, Rao J, Wang J, Wang P et al. Transcranial Direct Current Stimulation for Parkinson’s Disease: A Systematic Review and MetaAnalysis. Front Aging Neurosci. 2021;13:746797. https://doi.org/10.3389/FNAGI.2021.746797.Dobbs B, Pawlak N, Biagioni M, Agarwal S, Shaw M, Pilloni G et al. Generalizing remotely supervised transcranial direct current stimulation (tDCS): feasibility and benefit in Parkinson’s disease. J Neuroeng Rehabil. 2018;15(1):114. https://doi.org/10.1186/S12984-018-0457-9.Dobbs B, Pawlak N, Biagioni M, Agarwal S, Shaw M, Pilloni G et al. Generalizing remotely supervised transcranial direct current stimulation (tDCS): feasibility and benefit in Parkinson’s disease. J Neuroeng Rehabil. 2018;15(1):114. https://doi.org/10.1186/S12984-018-0457-9.

The authors declare that there are no conflicts of interest present.